← Back to Search

Treatment Arm for Telemedicine (TIME Trial)

N/A

Waitlist Available

Led By Ronac Mamtani, MD, MSCE

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

TIME Trial Summary

This trial is testing whether a text-based e-triage can safely reduce the time needed for routine cancer care.

Eligible Conditions

Telemedicine
Patient Empowerment
Solid Tumors
Cancer

TIME Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Healthcare time

Secondary outcome measures

Health related quality of life as assessed by the Functional Assessment of Cancer Therapy-General (FACT-G)

Patient satisfaction as assessed by the Patient Satisfaction Questionnaire Short Form (PSQ-18)

Provider satisfaction as assessed by Net-Promoter Score

+2 more

TIME Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Treatment ArmExperimental Treatment1 Intervention

For patients in the intervention arm, symptoms and laboratory results will be assessed using the text-based e-triage 96 hours prior to their intended infusion date. The e-triage will consist of a standardized questionnaire and algorithm to evaluate symptoms and laboratory values. Patients with acceptable labs and minimal or no symptoms can opt to proceed directly to their immunotherapy infusion without an in-person office assessment.

Group II: Usual CareActive Control1 Intervention

Patients in the usual care arm will receive standard of care symptom monitoring including an in-person office assessment prior to their scheduled immunotherapy infusion.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Abramson Cancer Center at Penn MedicineLead Sponsor

387 Previous Clinical Trials

145,659 Total Patients Enrolled

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor

359 Previous Clinical Trials

105,059 Total Patients Enrolled

Ronac Mamtani, MD, MSCEPrincipal InvestigatorFaculty

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there open positions available in this research yet?

"According to the information hosted on clinicaltrials.gov, this medical study is still in its recruitment phase. The trial was posted on December 6th 2021 and it has been updated as recently as September 23rd 2022."

Answered by AI

What is the magnitude of enrollees in this experiment?

"Confirmed. According to the details found on clinicaltrials.gov, this investigation is actively searching for participants and was initially published on December 6th 2021. As of September 23rd 2022, 176 people are required from one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Text-based Intervention to Minimize the Time Burden of Routine Cancer Care

2021. "Text-based Intervention to Minimize the Time Burden of Routine Cancer Care". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05134636.